09:24 AM EST - MYND Life Sciences Inc. : Provided a corporate update on its operations and progress on its strategic initiatives to the end of Q2 2021. "A key difference between MYND and other psychedelic companies is that we are creating intellectual property by reducing to practice the bio-active forms of psychedelics to particular medical conditions. Applying psychedelic analogs to other medical conditions not currently being targeted for psychedelic analog therapies. Creating unique biomarkers for diagnosing and monitoring MDD, and responses to treatment of MDD. Finally, MYND is applying novel vaccine and immunotherapeutic approaches to disease of the central nervous system. In this way, we plan to differentiate ourselves with a focus on building long-term value for our shareholders." continued CEO Dr. Lyle Oberg. MYND Life Sciences Inc.
shares C.MYND are trading unchanged at $1.12.
